



2017 Eligible Measure Applicability (EMA) for Registry Data Submission of Individual Quality Measures

2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR REGISTRY DATA SUBMISSION

QPP Clinically Related Measure Analysis Used in EMA

Clinical Relation including an Outcome/High Priority Test of the 2017 Registry Data Submission of Individual Quality Measures

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
1	Diabetes Mellitus Foot Care	126	N/A	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation
		127	N/A	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
2	Chronic Obstructive Pulmonary Disease (COPD) Care	51	N/A	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
		52	N/A	Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy
		130	High Priority	Documentation of Current Medications in the Medical Record
<p>Note: When submitting #130, they are not subject to EMA for these clinically related measures. If quality measures #51 and/or #52 are submitted, it is expected to submit quality measure #130.</p>				
3	Asthma Care	110	N/A	Preventive Care and Screening: Influenza Immunization
		130	High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		398	Outcome	Optimal Asthma Care- Control Component
		444	High Priority	Medication Management for People with Asthma
<p>Note: When submitting #110, #130 or #226, they are not subject to EMA for these clinically related measures. If #398 and/or #444 are submitted, it is expected to submit quality measures 110, #130 and #226.</p>				
4	Hematology Care	67	N/A	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
		68	N/A	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
		69	N/A	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
		70	N/A	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
5	Melanoma Care	137	High Priority	Melanoma: Continuity of Care-Recall System
		138	High Priority	Melanoma: Coordination of Care
		224	High Priority	Melanoma: Overutilization of Imaging Studies in Melanoma
6	Osteoporosis Care	24	High Priority	Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older
		130	High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		418	N/A	Osteoporosis Management in Women Who Had a Fracture
		<p><i>Note: When submitting #130 or #226, they are not subject to EMA for these clinically related measures. It is expected to submit these quality measures if #24 and/or #418 are submitted. There is no requirement to submit both #24 and #418.</i></p>		
7	Appropriate Test/Treatment for Children	65	High Priority	Appropriate Treatment for Children with Upper Respiratory Infection (URI)
		66	High Priority	Appropriate Testing for Children with Pharyngitis
8	Acute Otitis Externa	91	High Priority	Acute Otitis Externa (AOE): Topical Therapy
		93	High Priority	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
9	Adult Sinusitis Care	331	High Priority	Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Overuse)
		332	High Priority	Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)
		333	High Priority	Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)
		334	High Priority	Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
10	Pathology Breast Cancer	99	N/A	Breast Cancer Resection Pathology Submitting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
		251	N/A	Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
11	Primary Open-Angle Glaucoma	12	N/A	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
		141	Outcome	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
12	Age-Related Macular Degeneration	14	N/A	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
		140	N/A	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
13	Cataract Care	191	Outcome	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
		192	Outcome	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
		303	Outcome	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
		304	Outcome	Cataracts: Patient Satisfaction within 90 Days following Cataract Surgery
		388	Outcome	Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy)
		389	Outcome	Cataract Surgery: Difference Between Planned and Final Refraction
		110	N/A	Preventive Care and Screening: Influenza Immunization
14	Adult Renal Disease Care	122	Intermediate Outcome	Adult Kidney Disease: Blood Pressure Management
		130	High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
<i>Note: When submitting #110, #130 or #226, they are not subject to EMA for these clinically related measures. If quality measure #122 is submitted, it is expected to submit quality measures #110, #130 and #226.</i>				
15	Adult Renal Catheter Care	329	Outcome	Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis
		330	Outcome	Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days
16	Pediatric Kidney Disease Care	327	High Priority	Pediatric Kidney Disease: Adequacy of Volume Management
		328	Intermediate Outcome	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL
17	Perioperative Care	21	High Priority	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
		23	High Priority	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
18	Coronary Artery Bypass Graft Care	165	Outcome	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate
		166	Outcome	Coronary Artery Bypass Graft (CABG): Stroke
		167	Outcome	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure
		168	Outcome	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration
		445	Outcome	Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)
19	Endoscopy and Polyp Surveillance	185	High Priority	Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
		320	High Priority	Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
		439	High Priority	Age Appropriate Screening Colonoscopy
20	Urinary Incontinence Care	48	N/A	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
		50	High Priority	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
21	Coronary Disease Care	6	N/A	Coronary Artery Disease (CAD): Antiplatelet Therapy
		7	N/A	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)
		118	N/A	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
		130	High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
<p>Note: When submitting #130 or #226 they are not subject to EMA for these clinically related measures. If quality measures #6, #7, and/or #118 are submitted, it is expected to submit quality measures #130 and #226.</p>				
22	Heart Failure Care	5	N/A	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
		8	N/A	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
		130	High Priority	Documentation of Current Medications in the Medical Record
<p>Note: When submitting #130, it is not subject to EMA for these clinically related measures. If #5 and/or #8 are submitted, it is expected to submit quality measure #130.</p>				
23	Cardiac Stress Imaging	322	High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients
		323	High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)
		324	High Priority	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients
24	Breast Surgery Care	262	High Priority	Image Confirmation of Successful Excision of Image-Localized Breast Lesion

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		263	N/A	Preoperative Diagnosis of Breast Cancer
		264	N/A	Sentinel Lymph Node Biopsy for Invasive Breast Cancer
25	Retinal Care	384	Outcome	Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery
		385	Outcome	Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery
26	Heart Rhythm Care	348	Outcome	HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate
		392	Outcome	HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation
		393	Outcome	HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision
27	Pathology Lung Cancer	395	Outcome	Lung Cancer Reporting (Biopsy/Cytology Specimens)
		396	Outcome	Lung Cancer Reporting (Resection Specimens)
28	Colonoscopy Care	130	High Priority	Documentation of Current Medications in the Medical Record
		425	N/A	Photodocumentation of Cecal Intubation
				<i>Note: When submitting #130, it is not subject to EMA for these clinically related measures. If quality measure #425 is submitted, it is expected to submit #130.</i>
29	Gynecological Care	422	High Priority	Performing Cystoscopy at the time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury
		432	Outcome	Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair
		433	Outcome	Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair
		434	Outcome	Proportion of Patients Sustaining A Ureter Injury at the Time of any Pelvic Organ Prolapse Repair
30	Headache Care	419	High Priority	Overuse of Neuroimaging for Patients with Primary Headache And a Normal Neurological Examination
		435	Outcome	Quality of Life Assessment For Patients With Primary Headache Disorders
31	Anesthesiology Care	424	Outcome	Perioperative Temperature Management

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		426	High Priority	Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU)
		427	High Priority	Post-Anesthetic Transfer of Care Measure: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU)
		430	High Priority	Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy
<i>Note: When submitting these clinically related measures, the expectation is that either quality measures #424, #426 and #430 OR #424, #427 and #430 would be submitted. There is no expectation that quality measures #426 and #427 would be submitted together.</i>				
32	Opioid Care	408	N/A	Chronic Opioid Therapy Follow-up Evaluation
		412	N/A	Documentation of Signed Opioid Treatment Agreement
		414	N/A	Evaluation or Interview for Risk of Opioid Misuse
33	Palliative Care	47	High Priority	Care Plan
		134	N/A	Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		342	Outcome	Pain Brought Under Control Within 48 Hours
<i>Note: When submitting #47 and/or #134, they are not subject to EMA for these clinically related measures. If #342 is submitted, it is expected to submit quality measures #47 and #134.</i>				
34	Preventive Care	112	N/A	Breast Cancer Screening
		113	N/A	Colorectal Cancer Screening
		130	High Priority	Documentation of Current Medications in the Medical Record
		317	N/A	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
<i>Note: When submitting #130 or #317, they are not subject to EMA for these clinically related measures. It is expected to submit these quality measures if #112 and/or #113 are submitted. There is no requirement to submit both #112 and #113.</i>				
35	Immunization Care	110	N/A	Preventive Care and Screening: Influenza Immunization
		111	N/A	Pneumococcal Vaccination Status for Older Adults

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
36	Parkinson's Disease	290	N/A	Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease
		291	N/A	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment
		293	High Priority	Parkinson's Disease: Rehabilitative Therapy Options
		294	High Priority	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed
37	Cancer End of Life	453	High Priority	Proportion Receiving Chemotherapy in the Last 14 Days of Life
		454	Outcome	Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life
		455	Outcome	Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life
		456	High Priority	Proportion Not Admitted To Hospice
38	Optimizing Patient Exposure to Ionizing Radiation	359	High Priority	Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description
		360	High Priority	Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies
		361	High Priority	Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry
39	Total Knee Replacement	350	High Priority	Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy
		351	High Priority	Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation
		352	High Priority	Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet

**2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR
REGISTRY DATA SUBMISSION**

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		353	High Priority	Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report
40	Inflammatory Bowel Disease	271	N/A	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment
		275	N/A	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor)
41	Dementia	282	N/A	Dementia: Functional Status Assessment
		283	N/A	Dementia: Neuropsychiatric Symptom Assessment
		286	High Priority	Dementia: Counseling Regarding Safety Concerns
		288	High Priority	Dementia: Caregiver Education and Support